Article Details
Retrieved on: 2022-10-24 10:04:34
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Novartis (NVS) said its oral drug iptacopan met the two main goal of a phase 3 trial by showing superiority over AstraZeneca's (AZN) Soliris ...
Article found on: seekingalpha.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here